Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HK inno.N Corporation (195940.KQ)
Cheongju-si, KR
Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of medical conditions. These include treatments for various infectious diseases, such as those caused by gram-positive and gram-negative bacteria, vancomycin-resistant Enterococcus faecium, acute bacterial sinusitis, bronchitis, and pneumonia. Their therapeutic offerings also extend to chronic illnesses like anemia, diabetes, hypertension (including cases with dyslipidemia), and hypercholesterolemia (covering primary and homozygous familial types), alongside solutions for hemodialysis. The firm develops drugs for gastrointestinal disorders such as GERD, EE, NERD, GU, and H. Pylori infections. In the oncology sector, HK inno.N provides treatments for non-small cell lung cancer, colorectal cancer, and both pleural and general mesothelioma. Additionally, they offer nutritional and intravenous therapeutic solutions. Beyond pharmaceuticals, the corporation supplies health and wellness products, including hangover relief drinks, ready-to-drink beverages, health supplements, functional foods, and active pharmaceutical ingredients. Its beauty division markets products under the bewants, ScalpMed, and KLEDERMA RX brands. The company maintains an international presence, exporting its diverse range of products to markets across Japan, Southeast Asia, Latin America, Europe, and the Middle East.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.44% | -6.64% | -14.12% | -16.67% | -13.79% | -9.73% | +7.91% | +33.73% | -34.31% | -34.31% | -34.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 5 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+18.5% ★ Q1'26: +4.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+22.9% ★ Q1'26: +48.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+8.0% ★ Q1'26: +2.7% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+10.4% Q1'26: +12.7% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+5.4% Q1'26: +6.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×3.33× Q1'26: 2.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 4 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
828.91B
est: 826.54B (+0.3%)
|
897.14B
est: 907.96B (-1.2%)
|
1.06T
est: 1.06T (+0.5%)
|
1.12T
1.10T – 1.14T
+5.6% YoY
|
1.19T
1.14T – 1.37T
+6.4% YoY
|
1.28T
1.23T – 1.39T
+7.3% YoY
|
| EBITDA |
102.65B
est: 107.18B (-4.2%)
|
126.14B
est: 112.35B (+12.3%)
|
156.63B
est: 130.86B (+19.7%)
|
138.22B
135.57B – 141.57B
+5.6% YoY
|
147.02B
140.48B – 169.75B
+6.4% YoY
|
157.80B
152.69B – 172.33B
+7.3% YoY
|
| EBIT |
63.88B
est: 70.13B (-8.9%)
|
86.40B
est: 72.92B (+18.5%)
|
110.88B
est: 84.93B (+30.5%)
|
89.71B
87.99B – 91.88B
+5.6% YoY
|
95.42B
91.17B – 110.17B
+6.4% YoY
|
102.42B
99.10B – 111.84B
+7.3% YoY
|
| Net Income |
47.20B
est: 47.38B (-0.4%)
|
61.58B
est: 62.94B (-2.2%)
|
75.70B
est: 75.49B (+0.3%)
|
92.76B
82.41B – 112.95B
+22.9% YoY
|
108.94B
96.90B – 136.19B
+17.4% YoY
|
125.52B
120.24B – 140.55B
+15.2% YoY
|
| SGA |
153.81B
est: 151.50B (+1.5%)
|
180.24B
est: 133.40B (+35.1%)
|
—
est: 155.38B (-100.0%)
|
164.12B
160.97B – 168.10B
+5.6% YoY
|
174.56B
166.80B – 201.55B
+6.4% YoY
|
187.36B
181.30B – 204.62B
+7.3% YoY
|
| EPS |
1,666.00
est: 1,673.19 (-0.4%)
|
2,174.69
est: 2,221.71 (-2.1%)
|
2,672.09
est: 2,664.59 (+0.3%)
|
3,274.38
2,908.91 – 3,986.83
+22.9% YoY
|
3,845.41
3,420.35 – 4,807.41
+17.4% YoY
|
4,430.75
4,244.38 – 4,961.07
+15.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dal-Won Kwak | Chief Executive Officer, President & Director | — | male |
| Geun-Seok Song | Executive Director | — | male |
| Hwi-mun Kang | Affiliate Executives | — | — |
| Seong-bin Cho | Affiliate Executives | — | — |
| WooSung Kim | CFO & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 195940.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
